Multidrug-resistant and extensively drug-resistant tuberculosis: The National Institute of Allergy and Infectious Diseases research agenda and recommendations for priority research

Journal of Infectious Diseases

Volumn 197, Issue 11, 2008, Pages 1493-1498

  Fauci, Anthony S ^a   Alston, Beverly ^a   Barry, Clifton E ^a   Augustine, Alison Deckhut ^a   Fenton, Matthew J ^a   Handley, F Gray ^a   Holland, Steven M ^a   Huebner, Robin E ^a   Jacobs, Gail ^a   Laughon, Barbara ^a   Lehrman, Sandra ^a   Makhene, Mamodikoe ^a   Mason, Robin M ^a   Olivier, Kenneth N ^a   Polis, Michael A ^a   Prevots, D Rebecca ^a   Sizemore, Christine ^a   Spinelli, Beth Ann ^a   Taylor, Katherine ^a   Touchette, Nancy A ^a,b   Via, Laura E ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; CORIXA; CYCLOSERINE; FAS 20013; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; MTB 72 F; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SQ 109; THIOAMIDE; TIBOTEC;

ALLERGY; CLINICAL TRIAL; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

BIOMEDICAL RESEARCH; HEALTH POLICY; HUMANS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 43949084039     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587904     Document Type: Review

References (24)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2008. Available at: http:// www.who.int/tb/ publications/global_report/2008/pdf/fullreport.pdf. Accessed 28 March 2008.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization. AIDS epidemic update: November 2007. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/ default.asp. Accessed 28 March 2008.
3. World Health Organization. XDR TB - extensively drug-resistant TB, November 2006: outcomes of the WHO Global Task Force on XDR TB, October 9-10. Available at: http:// www.who.int/tb/xdr/xdr_nov06_en.pdf. Accessed 28 March 2008.
4. World Health Organization. Tuberculosis fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Accessed 28 March 2008.
5. Centers for Disease Control and Prevention. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55:1176.
6. World Health Organization. Countries with XDR-TB: confirmed cases to date. Available at: http://www.who.int/tb/challenges/xdr/xdrmap_26feb08_en.pdf. Accessed 28 March 2008.
7. NIAID Tuberculosis Working Group. NIAID research agenda: multidrug-resistant and extensively drug-resistant tuberculosis. Available at: http://www3.niaid.nih.gov/topics/tuberculosis/Research/PDF/ MDRXDRTBresearchAgenda06-06-07.pdf. Accessed 28 March 2008.
8. World Health Organization/Stop TB Partnership. The global MDR-TB and XDR-TB response plan 2007-2008. Available at: http://www.stoptb.org/ resource_center/assets/documents/MDR-XDR%20RESPONSE %20PLAN%20PRODUCTION%20FINAL.pdf. Accessed 28 March 2008.
9. Gandhi NR, Moll R, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
10. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
11. Shah NS, Wright A, Gill-Han B, et al. Worldwide emergence of extensively drug-resistant TB. Emerg Infect Dis 2007; 13:380-7.
12. World Health Organization. XDR-TB news update: extensively drug-resistant tuberculosis. May 2007. Available at: http://www.who.int/tb/challenges/xdr/ news_may07.pdf. Accessed 28 March 2008.
13. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 2007; 13:780-2.
14. Li X, Zhang Y, Shen X, et al. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis 2007; 195:864-9.
15. Charles M, Pape JW. Tuberculosis and HIV: implications in the developing world. Curr HIV/AIDS Rep 2006; 3:139-44.
16. Centers for Disease Control and Prevention. Corrected: investigation of U.S. traveler with extensively drug resistant tuberculosis (XDR TB). CDC health update. 29 May 2007. Available at: http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV. asp?AlertNum=00261. Accessed 28 March 2008.
17. Falzon D, Scholten J, Infuso A. Tuberculosis monitoring - is it time toupdate European recommendations? Euro Surveill 2006; 11:20-5.
18. World Health Organization. WHOIS: tuberculosis treatment success under DOTS (percentage). Available at: http://www.who.int/whosis/indicators/ 2007TBCasesCuredDOTS/en/index.html. Accessed 28 March 2008.
19. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J Suppl 2002; 36:87s-94s.
20. National Institute of Allergy and Infectious Diseases. Tuberculosis. NIAID's role in addressing tuberculosis, drug-resistant TB, and TB in people with HIV/AIDS. Available at: http://www3.niaid.nih.gov/topics/tuberculosis/ Research/NIAIDsRole.htm. Accessed 28 March 2008.
21. Tomioka H. Current status of some anti-tuberculosis drugs and the development of new anti-tuberculosis agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006; 12:4047-70.
22. Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41:1638-47.
23. Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41:461-9.
24. Chintu C. Tuberculosis and human immunodeficiency virus co-infection in children: management challenges. Paediatr Respir Rev 2007; 8:142-7.